CZL-S092

• Description :

  CZL-S092 is a PLK4 inhibitor with an IC50 value of 0.9 nM and excellent selectivity over other PLK4 family members (PLK1, PLK2, and PLK3) . CZL-S092 exhibits anti-neuroblastoma activity in vitro (IMR-32 cells, IC50 = 1.143 μM) . CZL-S092 inhibits cell migration and halts the cell cycle and induces apoptosis. CZL-S092 can be used in studies of various cancers including neuroblastoma cancer[1].

• UNSPSC :

  12352005

• Target :

  Polo-like Kinase (PLK)

• Related Pathways :

  Cell Cycle/DNA Damage

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Smiles :

  CN(C1=CC=CC(F)=C1)C(CSC2=CC3=C(C(/C=C/C4=CC=CN=C4)=NN3)C=C2)=O

• Molecular Formula :

  C23H19FN4OS

• Molecular Weight :

  418.49

• References & Citations :

  [1]Liu N et al. Rational design of CZL-S092: A novel indazole-based PLK4 inhibitor targeting neuroblastoma through virtual screening and fragment-based drug design strategies. Eur J Med Chem. 2025 Jun 13;296:117867. doi: 10.1016

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  PLK4